OCS Oculis Holding AG
Price Chart
Executive Summary
Oculis reported Q1 2026 EPS of CHF -0.49 (vs consensus $-0.41), a miss of ~2.7% on a USD-converted basis. The company highlighted strong cash runway into 2H 2029 and key upcoming catalysts: OCS-01 DME Phase 3 topline data in June 2026, Licaminlimab DED precision-medicine readout around year-end, and an FDA SPA agreement for Privosegtor in optic neuritis. The EPS miss is modest for a pre-revenue biotech, and the pipeline milestones dominate the stock narrative.
Actionable Insight
The stock will trade on OCS-01 DIAMOND topline data expected in June 2026 — a binary catalyst for a potential first-in-class non-invasive DME treatment. Monitor for any pre-readout leaks or analyst days. The EPS miss is minor for a pre-revenue biotech; the cash runway and regulatory milestones are the key drivers.
Key Facts
- Q1 2026 net loss CHF 28.9M ($36.8M) vs CHF 33.2M ($36.9M) in Q1 2025
- Cash, cash equivalents, and short-term investments $277.6M as of March 31, 2026
- EPS CHF -0.49 (basic and diluted) for Q1 2026
- OCS-01 DIAMOND Phase 3 DME trials completed LPLV; topline data expected June 2026
- Licaminlimab PREDICT-1 DED trial in active site recruitment; topline around year-end 2026
- Privosegtor received FDA SPA agreement for PIONEER-1 registrational trial in optic neuritis
- R&D expenses CHF 14.0M ($17.9M) vs CHF 14.8M ($16.4M) in Q1 2025
- G&A expenses CHF 7.9M ($10.1M) vs CHF 5.5M ($6.1M) in Q1 2025
Financial Impact
Net loss of CHF 28.9M ($36.8M) for Q1 2026; cash burn rate ~$12.3M/quarter; cash runway into 2H 2029
Risk Factors
- OCS-01 Phase 3 DME trials may fail to meet primary endpoints, wiping out near-term upside
- Licaminlimab precision-medicine approach may not replicate Phase 2 genotype-driven efficacy in larger Phase 3
- Privosegtor PIONEER program faces long enrollment timelines and regulatory uncertainty despite SPA
- Cash burn may accelerate if multiple trials ramp simultaneously, shortening runway from 2H 2029
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3292319 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 11, 2026
2d ago
|
Press Release
| $10.98 awaiting T+5 | awaiting T+5 | — | $11.09 (+1.00%) |
|
Jun 9, 2026
4d ago
|
Press Release
| $10.74 awaiting T+5 | awaiting T+5 | — | $11.09 (+3.31%) |
|
May 29, 2026
14d ago
|
Press Release
| $22.71 $11.21 | ▲ +50.63% | ▲ +48.10% | $11.09 (+51.16%) |
|
May 11, 2026
4w ago
|
Press Release
| $30.41 $28.07 | ▼ −7.69% | ▼ −7.77% | $11.09 (−63.53%) |
|
May 11, 2026
4w ago
|
Press Release
| $30.41 $28.07 | ▼ −7.69% | ▼ −7.77% | $11.09 (−63.53%) |
|
May 7, 2026
5w ago
|
Press Release
| $31.09 $31.37 | ▲ +0.90% | ▼ −0.60% | $11.09 (−64.33%) |
|
May 5, 2026
5w ago
|
Press Release
| $27.75 $30.41 | ▲ +9.59% | ▲ +7.60% | $11.09 (−60.04%) |
|
Apr 20, 2026
7w ago
|
Press Release
| $28.61 $27.12 | ▼ −5.21% | ▼ −6.12% | $11.09 (−61.24%) |
|
Mar 16, 2026
12w ago
|
Press Release
| $26.02 $24.60 | ▼ −5.46% | ▼ −3.42% | $11.09 (−57.38%) |
|
Mar 3, 2026
14w ago
|
Press Release
| $27.72 $27.28 | ▼ −1.59% | ▼ −0.25% | $11.09 (−59.99%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access